Standard Dosing for Arexvy
Arexvy (respiratory syncytial virus vaccine, GSK) is given as a single intramuscular dose of 0.5 mL to adults aged 60 years and older. It uses a prefilled syringe and is injected into the deltoid muscle of the upper arm.[1][2]
Who Qualifies and Timing Recommendations
The FDA approves Arexvy for adults 60+ to prevent lower respiratory tract disease from RSV. The CDC's Advisory Committee on Immunization Practices recommends it for those 60-74 at increased risk (e.g., chronic conditions like heart or lung disease) and routinely for those 75+. There's no need for a second dose, unlike some other RSV vaccines, but providers may consider revaccination after two years in certain high-risk cases.[1][3]
How It Compares to Abrysvo and mRESVIA
Arexvy is a single-dose vaccine, matching mRESVIA (Moderna) but differing from Abrysvo (Pfizer), which requires one dose now but was initially studied with a two-dose schedule. All target adults 60+; Arexvy showed 94.1% efficacy against RSV lower respiratory tract disease in trials.[2][4]
Storage and Administration Details
Store Arexvy refrigerated at 36-46°F (2-8°C); do not freeze. Shake before use to mix the adjuvant. No diluent needed. It's contraindicated in those with severe allergic reactions to prior doses or components.[1][2]
Common Patient Questions on Boosters or Delays
No routine booster is recommended yet, but ongoing studies assess durability. If delayed, give as soon as possible—no restart needed. Side effects include injection site pain (most common), fatigue, and headache, typically mild and short-lived.[3][5]
[1]: FDA Arexvy Prescribing Information
[2]: CDC Arexvy VIS
[3]: CDC ACIP Recommendations
[4]: NEJM Arexvy Trial
[5]: GSK Arexvy Safety Data